The Latest Cardiac and Vascular News
New 6 French model accommodates a broader range of devices while maintaining the integrated design and deliverability of CrossFAST SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ — Vantis Vascular, a medical technology company developing innovative devices for vascular interventions, today…
The egnite Registry contributed de-identified, longitudinal data, linking serial echocardiograms with clinical outcomes, to help answer what happens to patients after a successful mitral transcatheter edge-to-edge repair (M-TEER) procedure. ALISO VIEJO, Calif., Oct. 13, 2026 /PRNewswire/…
Round of more than $6 million, led by Colle Capital Partners with support from Orlando Health Ventures, will fund completion of Sensydia’s ongoing ACOUSTIC‑1 study for the Cardiac Performance System (CPS™) and preparation for commercial launch LOS ANGELES, Oct. 13, 2026 /PRNewswire/ –…
DALLAS, Oct. 13, 2026 /PRNewswire/ — Koya Medical (“Koya”), a medical technology company advancing evidence-based therapies for vascular disease, has announced its participation in two upcoming investor conferences: Goldman Sachs Healthcare Private Company Conference — Andy Doraiswamy…
Southern California physician leader returns to Long Beach and Orange County, where his medical career began, to help advance cardiovascular care across MemorialCare. FOUNTAIN VALLEY, Calif., Oct. 12, 2026 /PRNewswire/ — MemorialCare—a leading nonprofit integrated health system in…
MINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support the continued development of Vivian™, the Company’s next-generation pediatric […]
Gator SCALES-WHF, an investigator-sponsored study at the University of Florida, shows effective decongestion of patients at imminent risk for hospital admission with minimal user, device or safety issues; 30-day admission for treatment failure or insufficient response was rare….
LUCERNE, Switzerland and NEW DELHI, Oct. 12, 2026 /PRNewswire/ — The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary…
Combination of Hēlo Thrombectomy System and Hēlo Return establish the first 510(k)-cleared platform compatible with continuous vacuum aspiration MENLO PARK, Calif., Oct. 12, 2026 /PRNewswire/ — Endovascular Engineering, Inc. (E2), a commercial-stage medical technology company focused on…
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve™ Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex’s commitment to expanding clinical evidence supporting the use of the F
